Propanc Biopharma Files S-1 for Nasdaq IPO Amid Pre-Revenue Status
Propanc Biopharma, Inc. (PRPC) filed an S-1 registration statement with the SEC on October 5, 2026, seeking a Nasdaq listing. The oncology-focused biotech has no approved products, reported $28.7M net loss for FY2025, and held $10.2M in cash. Its pipeline remains pre-clinical.
51CFO view：CFOs of pre-revenue biotechs must demonstrate deep ASC 730 R&D expense classification rigor and robust stock-based compensation modeling under ASC 718. SEC will closely review clinical trial accrual methodologies and assumptions — requiring CFOs to lead cross-functional FP&A teams with clinical operations, not just accountants.
Propanc Biopharma, Inc. (PRPC) filed an S-1 registration statement with the SEC on October 5, 2026, seeking a Nasdaq listing. The oncology-focused biotech has no approved products, reported $28.7M net loss for FY2025, and held $10.2M in cash. Its pipeline remains pre-clinical.
Source：SEC EDGAR · S-1 招股书备案